Shares of bluebird bio were down in trading after the U.S. Food and Drug Administration declined to review a Biologics License Application for the experimental CAR-T treatment idecabtagene vicleucel for multiple myeloma co-developed with Bristol Myers Squibb.

The FDA refused to fully review the marketing application for Zogenix’s treatment for seizures associated with Dravet syndrome.

Here is a look at BioSpace’s top 10 stories of 2018.

Innocoll received a Refusal to File letter from the United States Food and Drug Administration (FDA) for XARACOLL, the company’s product candidate for the treatment of postsurgical pain.